论文部分内容阅读
目的:对2型糖尿病患者联合应用罗格列酮与美吡达的治疗效果展开观察与分析。方法:选取该院收治的93例2型糖尿病患者为研究对象,根据随机数字原则将其分为对照组(46例)与观察组(47例)。对照组应用美吡达进行治疗,观察组则接受罗格列酮联合美吡达治疗,对两组患者的治疗效果进行统计与评价。结果:经治疗,观察组患者的糖化血红蛋白、空腹血糖、餐后2 h血糖下降程度显著大于对照组,数据差异具有统计学意义(P<0.05)。此外,两组患者均未出现严重并发症。结论:通过联合应用罗格列酮与美吡达对2型糖尿病患者展开治疗,可有效降低患者的血糖水平,减少并发症的发生,极大程度上促进其生存质量的提高,具有重要的临床应用价值。
Objective: To observe and analyze the therapeutic effect of rosiglitazone and pyridostigmine in patients with type 2 diabetes mellitus. Methods: Ninety-three patients with type 2 diabetes mellitus admitted to the hospital were enrolled in this study. They were divided into control group (n = 46) and observation group (n = 47) according to random number principle. The control group was treated with pethidine, and the observation group received rosiglitazone combined with piradal. The treatment effect was statistically evaluated in both groups. Results: After treatment, the degree of HbA1c, fasting blood glucose and 2-h postprandial blood glucose in observation group were significantly higher than those in control group (P <0.05). In addition, no serious complications occurred in both groups. CONCLUSIONS: The combination of rosiglitazone and pyridosteol in the treatment of type 2 diabetes patients can effectively reduce the patient’s blood glucose levels and reduce the incidence of complications, to a great extent to promote the quality of life of their patients with an important clinical Value.